Learn the importance of considering patient psychological traits, expectations, perception of patient relationship with the trial physician and staff, and social structure in efforts to understand the impact of the COVID-19 pandemic on clinical trials.
Placebo Response
Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more common than rheumatoid arthritis (RA).
A recent study published in Nature Human Behavior developed a methodology to understand and assess the role of physician expectation on the placebo response. Read more about this study here.
Erica Smith, VP of Business Development, speaks with Daniel Levin of The Bio Report Podcast about the Placebell©™ method to reduce the impact of the placeb response in drug development”.
Drug developers have been struggling with the placebo response for decades, as a strong placebo effect diminishes the ability to distinguish pharmacologic treatment efficacy of an experimental drug.
Erica Smith, VP of Business Development, discusses the benefits of the Placebell©™ approach in video interview at Biotech Showcase in San Francisco, CA.
Date: January, 2019